Article
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.
Clinical colorectal cancer - 1 Jun 2024
Kotani Daisuke, Takashima Atsuo, Kato Takeshi, Satoh Taroh, Masuishi Toshiki, Komatsu Yoshito, Shiozawa Manabu, Esaki Taito, Izawa Naoki, Takeuchi Shinji, Bando Hideaki, Iwasa Satoru, Hasegawa Hiroko, Yamaguchi Toshifumi, Taniguchi Hiroya, Ushida Yasunori, Oizaki Toshiya, Inoue Chiaki, Yoshino Takayuki
Abstract excerpt
BACKGROUND: The phase 3 BEACON CRC study demonstrated the survival benefits of encorafenib and cetuximab, with or without binimetinib (the BEACON triplet or doublet regimen), for BRAFV600E-mutant metastatic colorectal cancer (mCRC). This expanded access program (EAP) and subsequent follow-up study assessed the efficacy and safety of the BEACON triplet regimen in Japanese patients with BRAFV600E-mutant mCRC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.